2-Methoxyestradiol enhances p53 protein transduction therapy-associated inhibition of the proliferation of oral cancer cells through the suppression of NFκB activity

Acta Medica Okayama

Volumn 58, Issue 4, 2004, Pages 181-187

  Takata, Hidehiko ^a   Tomizawa, Kazuhito ^a   Matsushita, Masayuki ^a   Matsui, Hideki ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Gene therapy; Poly arginine; Protein therapy; TAT; Tumor

Indexed keywords

2 METHOXYESTRADIOL; ARGININE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; HALF LIFE TIME; HUMAN; HUMAN CELL; MOUTH CANCER; STATISTICAL SIGNIFICANCE;

CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL LINE, TUMOR; CELL MEMBRANE; DRUG THERAPY, COMBINATION; ESTRADIOL; HUMANS; MOUTH NEOPLASMS; NF-KAPPA B; PEPTIDES; RECOMBINANT FUSION PROTEINS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 4644342573     PISSN: 0386300X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Schwarze SR, Ho A, Vocero-Akbani A and Dowdy SF: In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science (1999) 285: 1569-1572.
2. Schwarze SR and Dowdy SF: In vivo protein transduction: Intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol Sci (2000) 21: 45-48.
3. Matsui H, Tomizawa K, Lu YF and Matsushita M: Protein Therapy: In vivo protein transduction by polyarginine (MR) PTD and subcellular targeting delivery. Curr Protein Pept Sci (2003) 4: 151-157.
4. Matsushita M, Tomizawa K, Moriwaki A, Li ST, Terada H and Matsui H: A high-efficiency protein transduction system demonstrating the role of PKA in long-lasting long-term potentiation. J Neurosci (2001) 21: 6000-6007.
5. Li ST, Matsushita M, Moriwaki A, Lu YF, Tomizawa K and Matsui H: Human immunodeficiency virus type I Tat potentiates extrasynaptic N-methyl-D-Aspartate receptor-mediated calcium influx and attenuates spatial learning. Annals Neurol (2004): in press.
6. Greenblatt MS, Bennett WP, Hollstein M and Harris CC: Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res (1994) 54: 4855-4878.
7. Takenobu T, Tomizawa K, Matsushita M, Li ST, Moriwaki A, Lu YF and Matsui H: Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells. Mol Cancer Ther (2002) 1: 1043-1049.
8. Zhu BT and Conney AH: Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res (1998) 58: 2269-2277.
9. Schumacher G, Kataoka M, Roth JA and Mukhopadhyay T: Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin Cancer Res (1999) 5: 493-499.
10. Ghosh R, Ott AM, Seetharam D, Slaga TJ and Kumar AP: Cell cycle block and apoptosis induction in a human melanoma cell line following treatment with 2-methoxyoestradiol: Therapeutic implications? Melanoma Res (2003) 13: 119-127.
11. Wood L, Leese MR, Leblond B, Woo LW, Ganeshapillai D, Purohit A, Reed MJ, Potter BV and Packham G: Inhibition of superoxide dismutase by 2-methoxyoestradiol analogues and oestrogen derivatives: Structure-activity relationships. Anticancer Drug Des (2001) 16: 209-215.
12. Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest (2001) 107: 241-246.
13. Garg A and Aggarwal BB: Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia (2002) 16: 1053-1068.
14. Kumar AP, Garcia GE, Orsborn J, Levin VA and Slaga TJ: 2-Methoxyestradiol interferes with NF kappa B transcriptional activity in primitive neuroectodermal brain tumors: Implications for management. Carcinogenesis (2003) 24: 209-216.
15. Mukhopadhyay T and Roth JA: Superinduction of wild-type p53 protein after 2-methoxyestradiol treatment of Ad5p53-transduced cells induces tumor cell apoptosis. Oncogene (1998) 17: 241-246.
16. Carothers AM, Hughes SA, Ortega D and Bertagnolli MM: 2-Methoxyestradiol induces p53-associated apoptosis of colorectal cancer cells. Cancer Lett (2002) 187: 77-86.
17. Tomizawa K, Iga N, Lu YF, Moriwaki A, Matsushita M, Li ST, Miyamoto O, Itano T and Matsui H: Oxytocin improves long-lasting spatial memory during motherhood through MAP kinase cascade. Nat Neurosci (2003) 6: 384-390.
18. Rodriguez MS, Desterro JM, Lain S, Lane DP and Hay RT: Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol (2000) 20: 8458-8467.
19. Ashcroft M, Taya Y and Vousden KH: Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol (2000) 20: 3224-3233.
20. Haupt Y, Maya R, Kazaz A and Oren M: Mdm2 promotes the rapid degradation of p53. Nature (1997) 387: 296-299.
21. Kubbutat MH, Jones SN and Vousden KH: Regulation of p53 stability by Mdm2. Nature (1997) 387: 299-303.
22. Reifenberger G, Liu L, Ichimura K, Schmidt EE and Collins VP: Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res (1993) 53: 2736-2739.
23. Bueso-Ramos CE, Manshouri T, Haidar MA, Yang Y, McCown P, Ordonez N, Classman A, Sneige N and Albitar M: Abnormal expression of MDM-2 in breast carcinomas. Breast Cancer Res Treat (1996) 37: 179-188.
24. Carothers AM, Hughes SA, Ortega D and Bertagnolli MM: 2-Methoxyestradiol induces p53-associated apoptosis of colorectal cancer cells. Cancer Lett (2002) 187: 77-86.
25. Mayo MW, Wang CY, Cogswell PC, Rogers-Graham KS, Lowe SW, Der CJ and Baldwin AS Jr: Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science (1997) 278: 1812-1815.
26. Mosialos G: The role of Rel/NF-kappa B proteins in viral oncogenesis and the regulation of viral transcription. Semin Cancer Biol (1997) 8: 121-129.
27. Reuther JY, Reuther GW, Cortez D, Pendergast AM and Baldwin AS Jr: A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev (1998) 12: 968-981.
28. Jo H, Zhang R, Zhang H, McKinsey TA, Shao J, Beauchamp RD, Ballard DW and Liang P: NF-kappa B is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis. Oncogene (2000) 19: 841-849.
29. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T and Hannon GJ: Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature (1995) 377: 552-557.
30. Waldman T, Kinzler KW and Vogelstein B: p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res (1995) 55: 5187-5190.
31. Klauber N, Parangi S, Flynn E, Hamel E and D'Amato RJ: Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res (1997) 57: 81-86.